First transcatheter aortic valve implantation for severe pure aortic regurgitation in Asia.
- Author:
Paul Toon-Lim CHIAM
1
;
See Hooi EWE
;
Yeow Leng CHUA
;
Yean Teng LIM
Author Information
1. Department of Cardiology, National Heart Centre, 17 Third Hospital Avenue, Mistri Wing, Singapore 168752. paul.chiam.t.l@nhcs.com.sg.
- Publication Type:Case Reports
- MeSH:
Adult;
Aortic Valve;
surgery;
Aortic Valve Insufficiency;
surgery;
Aortic Valve Stenosis;
surgery;
Asia;
Echocardiography;
Endocarditis;
complications;
therapy;
Fluoroscopy;
Heart Valve Prosthesis;
Hemodynamics;
Humans;
Male;
Prosthesis Design;
Prosthesis Implantation;
methods;
Treatment Outcome
- From:Singapore medical journal
2014;55(2):103-105
- CountrySingapore
- Language:English
-
Abstract:
Transcatheter aortic valve implantation (TAVI) has become the standard of care for inoperable patients with symptomatic severe aortic stenosis (AS), and an alternative to open aortic valve replacement for patients at high surgical risk. TAVI has also been performed in several groups of patients with off-label indications such as severe bicuspid AS, and as a valve-in-valve therapy for a degenerated surgical bioprosthesis. Although TAVI with CoreValve® prosthesis is technically challenging, and global experience in the procedure is limited, the procedure could be a treatment option for well-selected patients with severe pure aortic regurgitation (AR). Herein, we report Asia's first case of TAVI for severe pure AR in a patient who was at extreme surgical risk, with good clinical outcome at six months.
